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Abstract
Background: The consensus documents published to date on hereditary angioe-
dema with C1 inhibitor deficiency (C1-INH-HAE) have focused on adult patients.
Many of the previous recommendations have not been adapted to pediatric
patients. We intended to produce consensus recommendations for the diagnosis
and management of pediatric patients with C1-INH-HAE.
Methods: During an expert panel meeting that took place during the 9th C1 Inhi-
bitor Deficiency Workshop in Budapest, 2015 (www.haenet.hu), pediatric data
were presented and discussed and a consensus was developed by voting.
Results: The symptoms of C1-INH-HAE often present in childhood. Differential
diagnosis can be difficult as abdominal pain is common in pediatric C1-INH-HAE,
but also commonly occurs in the general pediatric population. The early onset of
symptoms may predict a more severe subsequent course of the disease. Before the
age of 1 year, C1-INH levels may be lower than in adults; therefore, it is advisable
to confirm the diagnosis after the age of one year. All neonates/infants with an
affected C1-INH-HAE family member should be screened for C1-INH deficiency.
Pediatric patients should always carry a C1-INH-HAE information card and medi-
cine for emergency use. The regulatory approval status of the drugs for prophylaxis
and for acute treatment is different in each country. Plasma-derived C1-INH, recom-
binant C1-INH, and ecallantide are the only agents licensed for the acute treatment
of pediatric patients. Clinical trials are underway with additional drugs. It is recom-
mended to follow up patients in an HAE comprehensive care center.
Conclusions: The pediatric-focused international consensus for the diagnosis and
management of C1-INH-HAE patients was created.
Abbreviations
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Allergy
Hereditary angioedema with C1 inhibitor deficiency (C1-
INH-HAE) is a rare autosomal dominant disorder due to
either deficiency (type I, 85% of cases) or dysfunction
(type II, 15% of cases) of the serine protease inhibitor
(serpin) C1 inhibitor (C1-INH). A less common form of
hereditary angioedema has a positive family history, but
normal C1-INH protein quantity and function: In some
cases, the disease appears to be related to factor F12 gene
defects (FXII-HAE), while in most cases, the cause of this
form of angioedema remains unknown (U-HAE). This con-
sensus addresses only C1-INH-HAE in the pediatric ages
of birth until 18th birthday. Angioedema is due to the
leakage of plasma from postcapillary venules mediated by
the unregulated generation of bradykinin (1). C1-INH-
HAE is characterized by recurrent attacks of nonpruritic,
nonpitting subcutaneous, and/or submucosal angioedema
that can affect any part of the body. Publications on clini-
cal manifestations combining pediatric and adult patients
show that skin involvement is the most frequent location
of the edema (91% of patients) followed in frequency by
abdominal attacks (73%) and upper airway edema (48%)
(2). Viewing per-episode, nearly all episodes consisted of
skin swellings and abdominal attacks (96.5%). Per-episode,
laryngeal events are rare (0.9%), but potentially life threat-
ening (3). One-third of patients may develop an erythema-
tous, nonpruritic rash, erythema marginatum, which might
precede or accompany angioedema, although it can also
occur independently (4). Sudden swellings of the gastroin-
testinal mucosa are common and often associated with sev-
ere debilitating abdominal pains. In one-quarter of
patients, severe abdominal pain may be the initial symp-
tom. Acute abdominal pain mimics acute abdomen and
may lead to unnecessary abdominal surgery. Edema involv-
ing the submucosa of the upper airways may cause airway
obstruction and without treatment may lead to suffocation
and death. The reported age of onset of attacks varies
from 4.4 to 18 years with mean age of first attack at the
age of ten (3, 5–13). Early onset of symptoms may predict
a more severe course of disease (3, 14, 15). HAE attacks
usually become more severe at puberty particularly in
females and swellings may occur for the first time with the
introduction of estrogen-containing medications (16, 17).
The diagnosis of C1-INH-HAE is often delayed for years
because of the rarity of the disease and of the fact that its
symptoms overlap with those of other forms of
angioedema. The time between the onset of symptoms and
diagnosis averages 8.5 years (18). The diagnosis of
C1-INH-HAE type II may be limited by the availability of
testing for functional C1-INH level. In patients without a
positive family history or with C1-INH-HAE type II, delay
in diagnosis is usually longer (6, 9, 11, 12, 18–20). The
utility of antifibrinolytics and androgens in C1-INH-HAE
prophylaxis and plasma-derived C1-INH (pdC1-INH) in
replacement therapy have long been recognized. In recent
years, other novel therapies have become available with
efficacy proven by double-blind studies mostly conducted
in adults. International consensus publications on HAE
have mostly been relevant to adult C1-INH-HAE (21–23).
Pediatric-focused international consensus for the diagnosis
and management of C1-INH-HAE patients has not been
previously published. This report presents international
consensus for the diagnosis and management of C1-INH-
HAE in the pediatric age group.
Methods
Bibliographic search
Data sources
A PubMed search (last updated December 31, 2015) was
performed using the following key words: hereditary
angioedema, C1 inhibitor, C1 inhibitor deficiency, pedia-
trics, adolescence, children, diagnosis, treatment, consensus,
guidelines; additional titles from the reference lists of pub-
lished articles in English language; additional data from
abstracts known to the authors.
Discussion
An expert panel meeting and Round Table discussion took
place during the 9th C1 Inhibitor Deficiency Workshop in
Budapest on May 30, 2015 (www.haenet.hu). Data were pre-
sented followed by discussion and consensus was determined
by voting.
Evidence level
The levels of evidence to support the views expressed in this
document will be indicated in accordance with the U.S.
Preventive Services Task Force Guidelines for ranking evi-
dence on the effectiveness of treatments or screening, U.S.
Preventive Services Task Force, August 1989 (Guide to clini-
cal preventive services: Report of the U.S. Preventive Task
Force. DIANE Publishing. p. 24. ISBN 9781568062976)
(Table 1).
Table 1 Levels of evidence (U.S. Preventive Services Task Force
for ranking evidence about the effectiveness of treatments or
screening)
Levels Description
I Evidence obtained from at least one properly designed
randomized controlled trial.
II-1 Evidence obtained from well-designed controlled
trials without randomization.
II-2 Evidence obtained from well-designed cohort or
case–control analytic studies, preferably from more
than one center or research group.
II-3 Evidence obtained from multiple time series with or
without the intervention.
Dramatic results in uncontrolled trials might also
be regarded as this type of evidence.
III Opinions of respected authorities, based on
clinical experience
Descriptive studies
Reports of expert committees
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Results
Clinical symptoms
Similar to adults, clinical events in pediatric patients with
C1-INH-HAE are characterized by recurrent subcutaneous
and/or submucosal edematous episodes without wheals or
pruritus, and if untreated, the edema may persist for 1 to
5 days before resolving spontaneously (24).
Onset of symptoms
In C1-INH-HAE, attacks may occur at any age after birth,
but in utero angioedema symptoms have not been reported.
The presence of a fetus with C1-INH-HAE may affect the
number of maternal attacks (25, 26). The nature of C1-INH
transport across the placental barrier is unclear, but likely
requires active transport. Although C1-INH deficiency is pre-
sent at birth, clinical symptoms are rare during infancy. New-
borns may experience erythema marginatum as a prodromal
symptom, but rarely swelling (4, 27). The reported age of
onset of attacks varies from 4.4 to 18 years with mean age of
first attack at the age of ten (3, 5–13). Colic may be an
unrecognized symptom of C1-INH-HAE in infancy (28–30).
Early onset of symptoms may predict a more severe subse-
quent course of disease (3, 14, 15).
Frequency and severity of symptoms
The frequency and severity of the symptoms exhibit a sub-
stantial inter- and intraindividual variation. Symptoms often
worsen during puberty, particularly in females (3, 14, 31, 32).
Onset of symptoms may occur with the introduction of estro-
gen-containing medications for acne or birth control (17).
The role of puberty in boys is less obvious.
Trigger factors
A multitude of factors may trigger edematous episodes in
C1-INH-HAE at any age (33). In children, most attacks
occur without a clear trigger. However, the most common
attack triggers include mechanical trauma, mental stress, and
airway infections (14, 34). Although dental eruption is not a
frequent trigger for angioedema attacks, it could act as a
provoking factor in some children (34). In adolescent girls,
menstruation and ovulation are additional triggers (31). Cer-
tain medicines (such as estrogen-containing oral contracep-
tives, angiotensin-converting enzyme inhibitors, ACEIs) can
trigger attacks (35, 36).
Location of symptoms
Subcutaneous edema. Subcutaneous edema of the extremities
is often the earliest and most common swelling site in pedi-
atric patients (3, 5, 14, 37, 38). Subcutaneous swelling is a
common cause of school absenteeism and may affect a child’s
progress in school and participation in sports and other daily
activities (14, 34).
Submucosal edema. Bowel—Bowel wall edema and related
symptoms of colicky abdominal pain, nausea, vomiting, and
postattack watery diarrhea are common (80–90%) in the
pediatric patient population (3, 5, 14, 37). As abdominal pain
is frequent in the general pediatric population, the wide dif-
ferential diagnosis must always be considered including acute
appendicitis, mesenteric lymphadenitis, intussusception, par-
tial malrotation with intestinal torsion, Meckel’s diverticu-
lum, polycystic ovaries, ovarian or testicular torsion,
intestinal hemorrhage or infarction, recurrent peritonitis of
familial Mediterranean fever, and other abdominal diseases.
Afflicted patients are often admitted to a surgical department
for observation and at times subjected to an unnecessary
operation. Abdominal ultrasound or CT scan may be per-
formed to help exclude acute surgical abdominal disease (29,
30, 39–44). Abdominal ultrasound may be a sensitive, rapid,
and noninvasive differential diagnostic modality in patients
with known C1-INH-HAE to help differentiate acute
appendicitis and monitor response to event intervention with
C1-INH-HAE therapeutic agents (43, 45, 46). Clinical and
ultrasound response to specific C1-INH-HAE therapeutic
medications helps differentiate C1-INH-HAE from non-
C1-INH-HAE-related abdominal events. Standard biochemi-
cal and hematological blood tests are often not helpful in
abdominal attacks to discriminate C1-INH-HAE from non-
C1-INH-HAE events. Neutrophilia may occur secondary to
an HAE attack (47–49). Low C4 and low C1-INH functional
levels during an abdominal attack might be retrospectively
helpful in confirming that abdominal symptoms are related
to C1-INH-HAE. Commonly, the results of these tests are
not available in time to be of help during the acute event.
Upper airway edema (UAE)—It usually first occurs between
11 and 45 years of age, with the mean age of 26. The earliest
laryngeal edema recorded has been 3 years of age (14, 50).
Although UAE is usually not the first presenting symptom of
C1-INH-HAE, it may be the first presenting event and this first
event may be fatal (50, 51). Death from asphyxiation may
occur at any age with mean age at asphyxiation of 40.6 years
(range: 9–78 years). Death by asphyxiation is less common in
pediatric C1-INH-HAE patients (50–52). Inspection of the lar-
ynx is more difficult in young patients and it takes less swelling
to asphyxiate in small children because of the smaller upper
airway diameter (53–55). The differential diagnosis in pedi-
atrics includes allergic food reactions, croup, pseudocroup, for-
eign body aspiration, and acute epiglottitis. For this reason,
airway protection is the main task for the emergency depart-
ment even when specific therapy for C1-INH-HAE is not avail-
able or it is not promptly administered (56, 57).
Other locations. Edema can occur at any site including the
urinary bladder, urethra, genitalia, kidneys, muscles, joints,
pericardial or pleural spaces and can be associated with neu-
rological symptoms associated with headache, transient visual
disturbances, and migraine-like symptoms in pediatrics (3,
14, 58).
Prodromal symptoms
Of pediatric patients with C1-INH-HAE, 42% to 58% expe-
rience prodromal symptoms including erythema marginatum
(a map-like rash on the skin; reported from newborn
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onward) (4, 6, 14). Skin lesions with a similar appearance
may develop in viral and bacterial infections and autoinflam-
matory diseases including rheumatoid diseases and periodic
fever syndromes. The rash may be misdiagnosed as urticaria
and C1-INH-HAE patients with erythema marginatum have
a longer diagnostic delay (27, 59–61).
Concomitant disease
A higher incidence of concomitant celiac disease has been
observed in C1-INH-HAE pediatric patients. In celiac pedi-
atric HAE patients, celiac dietary restriction may reduce
abdominal symptoms (62).
Diagnosis
Prenatal
Prenatal diagnosis may be considered when a disease-caus-
ing mutation has been detected in a C1-INH-HAE family.
If the family would consider pregnancy termination with
the diagnosis of an affected fetus and varying with local
ethical restrictions, then prenatal diagnosis of C1-INH-
HAE may be achieved by chorionic villous sampling or
amniocentesis (63). C1-INH-HAE has a highly variable dis-
ease severity within and between families with poor correla-
tion between gene defect and clinical severity. Advances in
therapy have significantly improved the health-related qual-
ity of life (HRQoL) of patients. Therefore, the decision
whether to perform prenatal diagnosis should be made by
the parents following appropriate counseling and the care-
ful evaluation of benefits and risks. Preimplantation diagno-
sis and implantation of unaffected fetuses is under
consideration in some jurisdictions. No mutation can be
detected in the C1-INH (SERPING1) gene in 8–10% of
C1-INH-HAE (64–67).
Postnatal
Blood laboratory testing. Blood testing to diagnose C1-INH-
HAE in pediatrics is similar to adults (21). Low functional
C1-INH with low C4 suggests C1-INH-HAE at all ages, but
requires confirmation. When accompanied by a low antigenic
C1-INH level, then C1-INH-HAE type I is possible. If low
C4 and low functional C1-INH are associated with normal
or elevated antigenic C1-INH levels, then C1-INH-HAE type
II is likely. These testings should be repeated to confirm the
diagnosis of C1-INH-HAE (68).
Acquired angioedema with C1-INH deficiency (antibody
or C1-INH consumption-mediated or B-cell dyscrasia set-
tings) is usually seen only in adults and is unlikely under
40 years of age. Therefore, C1q is usually not indicated for
testing in the pediatric ages. C2, C3, and CH50 testing are
not indicated for C1-INH-HAE diagnosis at any age. Some
immunoregulatory disorders and congenital complement defi-
ciencies other than C1-INH-HAE should be kept in mind,
however, and further complement investigations may be car-
ried out as clinically indicated particularly if negative family
history. C1-INH-HAE-like events have been seen in congeni-
tal C4 deficiencies or early-onset lupus-like disorders, and in
these cases, testing the other complement components may
be indicated (69).
In families with known C1-INH-HAE, first-degree rela-
tives, whether symptomatic or asymptomatic, should be
screened with C1-INH (preferably functional) and C4 levels
at earliest convenience. The first swelling may be upper air-
way and may be fatal and come on without warning
(Fig. 1A).
Genetic testing. Genetic testing is not required to confirm the
diagnosis of C1-INH-HAE unless prenatal testing is consid-
ered or in rare cases where a differential diagnosis is required
in newborns and infants. Genetic testing may be helpful bear-
ing in mind that not all of the mutations detected by routine
genetic testing are undoubtedly disease causing (65). The
detection of disease-associated mutations requires a meticu-
lous analysis of the gene and, possibly, the genetic testing of
other affected and disease-free family members. When genetic
testing is available and a known family mutation is detected,
then DNA analysis from cord blood or peripheral blood is
sufficient to establish the diagnosis (Fig. 1A).
Diagnosis under the age of one year. Asymptomatic newborns
or infants with a family history of C1-INH-HAE should be
considered to have hereditary C1-INH deficiency until the
diagnosis is ruled out. C1-INH levels are normal or even ele-
vated from ages of one to five years compared to adults (70),
but before the age of 1 year, the antigenic and functional C1-
INH levels may be lower than in adults, with the lowest
levels in umbilical cord blood (71, 72). Both antigenic and
functional C1-INH cord blood levels correspond to 70% and
61.8% of adult normal values increasing to normal adult
levels by the age of one year (71, 72). Moreover, neonatal
serum complement levels are influenced by birth weight and
gestational age (71, 73, 74). In newborns and infants aged
less than 1 year, both C1-INH antigenic level and functional
activity are low in the patients with C1-INH-HAE type I and
are within normal range in non-C1-INH-HAE patients (68,
72). However, under one year of age, C4 levels are frequently
low in non-C1-INH-HAE patients as well. Therefore, testing
for C1-INH antigenic and functional levels are helpful to
diagnose C1-INH-HAE regardless of the age of the patient,
but low C4 levels under one year of age are not diagnostic
for C1-INH-HAE (68).
If C1-INH antigenic and functional levels are normal in a
newborn or infant, the diagnosis of C1-INH-HAE is unlikely
but confirmation after the age of one year is advisable. If
functional and/or antigenic C1-INH levels are low in a new-
born or infant with suspected C1-INH-HAE, then we suggest
repeating the testing after the age of one year. A final diag-
nosis requires at least two matching HAE screening results
with the second test performed after one year of age (72, 75).
If the familial gene is known, then C1-INH-HAE diagnosis
in a newborn or infant can be helped by genetic testing
(Fig. 1A).
Diagnostic testing if patient history suggestive of C1-INH-
HAE, but negative family history. Negative family history
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Figure 1 The diagnosis of C1-INH deficiency in families with known C1-INH-HAE (A) and the diagnosis of C1-INH-HAE in pediatric patients
with angioedema of unknown etiology (B).
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does not rule out C1-INH-HAE. Clinical suspicion of C1-
INH-HAE-like symptoms at any age is an indication for
screening regardless of the presence or absence of family
history. C1-INH-HAE screening includes functional and
antigenic C1-INH levels and C4. If screening is suggestive of
C1-INH-HAE, a second test should be performed to confirm
the diagnosis. If C1-INH-HAE is suggested by testing, then
all first-degree relatives in the ascending line should be
screened (including symptom-free individuals). As with many
autosomal dominant disorders, 25% of cases may be a de
novo mutation which may then be passed onto future descen-
dants (76). SERPING1 gene sequencing may be helpful to
confirm the C1-INH-HAE in this setting (64, 66). If screening
is negative for C1-INH deficiency, angioedema with acquired
C1-INH deficiency is also excluded, but HAE with normal
C1-INH function, which is very rare in pediatric patients, is
not ruled out (Fig 1B).
Management
Diagnosis and management of C1-INH-HAE are best
achieved through comprehensive care clinics (level III evi-
dence).
Education and counseling
Education of patients and their family members, family
physicians, and consultant specialists including pediatricians
with respect to diagnosis and therapy of C1-INH-HAE is the
cornerstone of successful management of C1-INH-HAE in
all age groups, but especially in pediatrics (level III evidence)
(14, 22, 77–79). Parents should be provided with comprehen-
sible information on specific characteristics of C1-INH-HAE
and on management options for all age groups at the time of
diagnosis and with each follow-up comprehensive care HAE
clinic visit. Furthermore, distance communication options
should be made available including telephone and Internet
access to the clinic (14). It is important that teachers and
responsible child care workers receive detailed written infor-
mation on the disease (14, 22). Because young children might
not be able to correctly describe their condition, they should
always carry a multilingual C1-INH-HAE identification and
information card containing a description of emergency pro-
cedures along with acute treatment products for emergency
use (see below for acute treatment options). Alert devices,
including identifying wrist or neck bands with emergency
contact information, should also be considered (22, 80). A
detailed individual action and treatment plan should be pro-
vided to the families. Self- or assisted treatment techniques
should be discussed and training programs for these offered
(7, 22, 81).
Primary prevention
Avoidance of C1-INH-HAE triggers. As described in Sec-
tion Trigger factors above, some medications may trigger C1-
INH-HAE events including ACEIs and estrogen-containing
oral contraceptives. These agents should be avoided in C1-
INH-HAE patients of all ages whenever possible (14, 31, 33,
35, 36). In some cases, attacks can be prevented through
counseling, lifestyle changes, and by avoiding triggering fac-
tors, most specifically contact sports and other activities
involving physical tissue trauma. Although breastfeeding is
known to confer protection against numerous diseases, it
does not decrease nor prevent C1-INH-HAE and its symp-
toms (82). Immunizations are usually recommended for pedi-
atrics with C1-INH-HAE and we suggest the usual schedule
for vaccination. The aim of C1-INH-HAE management at all
ages should be to normalize activities and lifestyle whenever
possible. With the availability of modern effective therapeutic
and prophylactic interventions, patients should be encour-
aged to lead as normal a lifestyle as possible. There is no rec-
ommendation for specific activity avoidance (34).
Genetic management approaches. Gene therapy at various
levels and genetic corrective interventions are under study,
but not yet available. Preselection of unaffected embryos for
implantation is under consideration in some jurisdictions
(63).
Drug treatment
Prophylaxis. As indicated above, prophylaxis begins with
identification and elimination or avoidance of precipitating
factors, if possible (34, 38). Therapeutic prophylaxis usually
includes either short-term prophylaxis (STP) before events
that are at an increased risk of precipitating an attack or
long-term prophylaxis (LTP), which would be used to pre-
vent attacks long term. So far, no randomized controlled tri-
als (RCTs) on prophylactic treatment restricted to the
pediatric population have been conducted. Few pediatric
patients have been included in RCTs (no level I evidence)
leaving most pediatric prophylaxis level III evidence (14, 21,
22, 34, 38, 78, 83–85).
Short-term prophylaxis—As in adults, indications for STP in
pediatrics include patient-specific triggers, medical and dental
procedures (85). For most ‘minor interventions’, the recom-
mendation is to choose on-demand treatment if a swelling
event is precipitated rather than prophylaxis, provided that a
licensed on-demand medication is immediately available in
the case of emergency (level III evidence). For interventions
that involve airway manipulation or that might lead to tissue
swelling, prophylaxis with a dose of 15 to 30 units per kg
pdC1-INH (Berinert [pdC1-INHBe]) concentrate is recom-
mended. There are no studies supporting appropriate timing
of the STP nor consensus on the recommended maximum
dose (1000 units versus 15 to 30 units/kg) (level III evidence)
(14, 21, 22, 34, 78, 83–85). STP with pdC1-INH recommen-
dations varies from during procedure or one or more hours
before the procedure trying to give as close to the procedure
as possible. If licensed on-demand acute treatment medica-
tion is not available with planned procedures, the following
treatment options are recommend for STP: oral attenuated
androgens (AAs), mainly danazol 2.5 to 10 mg/kg/day, mean
dose suggestion 5 mg/kg/day (maximum 600 mg daily) (sta-
nozolol and oxandrolone being used less often); or
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antifibrinolytics like tranexamic acid (TA) 20 to 50 mg/kg/
day split into 2 or 3 doses with a maximum of 3 to 6 g/day,
considering dose adjustment for renal impairment (epsilon
aminocaproic acid is used less often). Prophylaxis should
start (at least) 5 days before and be continued for 2 days
postprocedure (level III evidence). As prophylaxis may fail,
effective on-demand treatment should be available whenever
possible (level III evidence) (14, 21, 22, 34, 78, 83–85). In
emergency situations and when licensed on-demand therapies
are not available, 10 ml/kg of solvent detergent plasma
(SDP) (safer than fresh frozen plasma (FFP)) may be used
prophylactically pre- or perioperatively or on-demand (level
III evidence).
Long-term prophylaxis—As with adults, indications and
options for long-term prophylaxis (LTP) are controversial for
pediatric C1-INH-HAE patients. LTP should be considered
to minimize the impact of C1-INH-HAE on patients’ QoL.
Agents for LTP include antifibrinolytics (tranexamic acid,
TA; epsilon aminocaproic acid), AAs (danazol, stanozolol,
oxandrolone), and pdC1-INH.
Most consider TA to be the agent of choice for LTP in
pediatrics, but TA is contraindicated for patients with a his-
tory of thromboembolism or a known thrombophilia defect
(level III evidence). Patients with a family history of known
thrombophilia defect should be screened for the defect before
receiving LTP with TA (although the occurrence of throm-
botic events is very rare). There are few data regarding the
appropriate dose of TA with 20 to 50 mg/kg/day split into 2
or 3 doses with a maximum of 3 to 6 g/day mainly used for
LTP (dose adjustment for renal impairment; level III evi-
dence). We recommend starting at the lower dose and
increasing as needed to suppress events. When antifibrinolyt-
ics fail to achieve the desired improvement or if they are
contraindicated or not tolerated, then most recommend
pdC1-INH for LTP (level III evidence).
AAs are usually not considered for LTP in pediatrics prior
to Tanner Stage V. After Tanner Stage V, AAs may be used
trying to achieve the minimum effective dose. Danazol has
been used effectively in pediatrics at doses of 2.5 to 5 mg/kg/
day (200 mg daily should not be exceeded). Treatment
should start at 2.5 mg/kg/day and increase slowly every
2 weeks until symptom suppression or the maximum toler-
ated or maximum recommended dose is reached. AA admin-
istration requires careful safety monitoring (14, 34). Dosage
for oxandrolone has not been established for pediatrics,
although some suggest that this is the preferred androgen for
pediatric patients. The initial dose for adults is 2.5 mg three
times daily and the lowest dose to control the attacks should
be reached. Church JA reported the use of 0.1 mg/kg/day in
a child and virilizing effects were seen. The drug has to be
formulated so decreasing concentrations could be tried (level
III evidence) (86, 87).
PdC1-INH may be the safest LTP approach (level III evi-
dence) and recommended over AA LTP where possible.
LTP does not necessarily mean uninterrupted medication
for life. As events change (e.g., changes in stressors or hor-
monal fluxes), a step-up, stabilize, step-down, or intermittent
approach to LTP may be a consideration. In general, inter-
mittent LTP may be appropriate in some patients, while
others may require continuous LTP (level III evidence). We
recommend a pdC1-INH LTP dose of 10 to 20 units per kg
per dose once or twice weekly with an initial maximum dose
of 1000 units (level III evidence). The safety and effectiveness
of pdC1-INH has not been established in pediatrics. Three of
the 24 subjects in the randomized, placebo-controlled, cross-
over, routine prophylaxis trial with pdC1-INH (Cinryze
[pdC1-INHCi]) were under the age of 18 years (9, 14, and
16 years of age). Data on pediatric IV pdC1-INH LTP dose
and frequency are very limited and we are awaiting the
results of ongoing pediatric pdC1-INHCi study and the
results of controlled clinical trials of subcutaneous pdC1-
INH in preventing HAE attacks in this age group. Combina-
tion LTP approaches including intermittent LTP or combina-
tion LTP agents (e.g., TA plus pdC1-INH at various doses
and frequencies) need further consideration. To date, safety,
efficacy, and tolerability of pdC1-INH appear to be similar
in pediatric and adult patients (level III evidence), but
approval age and indication of various pdC1-INH concen-
trates vary by jurisdiction (14, 21, 22, 34, 78, 83–85, 88, 89).
Acute treatment. All swelling events are eligible for acute
treatment (level III evidence) (90).
Upper airway swellings should always receive acute treat-
ment as early as possible followed by immediate assessment
in the emergency room. Clinical trials suggest that earlier
treatment shortens attack duration and improve treatment
outcomes (level III evidence) (91–94).
Every patient with C1-INH-HAE should be considered for
home therapy and self-/caregiver administration training.
This can be facilitated through peer-to-peer encouragement
and training at summer camps with pediatric patients of var-
ied ages or by in-home nurse training (level I evidence).
Level I evidence for acute treatment of C1-INH-HAE has
been reviewed for pdC1-INHBe, pdC1-INHCi, recombinant
human C1-INH (rhC1-INH) (Rhucin/Ruconest), kallikrein
inhibitor ecallantide (Kalbitor), and bradykinin B2 receptor
antagonist icatibant (Firazyr) (85, 91, 92, 95–99). Unfortu-
nately, these treatments have been licensed mainly for adults
with pediatric licensing pending and ages for licenses varying by
jurisdiction. At present, pdC1-INH, rhC1-INH and ecallantide
(12 years and up; in Europe and USA, pdC1-INHBe is licensed
for all age groups) are the only agents licensed for pediatric
acute treatment (14, 21, 24, 34, 100). There are few reports of
use of pdC1-INH in very young children and babies (101, 102).
Plasma-derived C1-INH concentrates—The plasma-derived
C1-INH concentrates (pdC1-INHBe and pdC1-INHCi) are
both approved for C1-INH-HAE acute treatment in pediatric
patients in Europe by the EMA (European Medicines
Agency) with doses of 20 units per kg for pdC1-INHBe
(pdC1-INHBe is approved by the EMA and FDA [Food and
Drug Administration] for all ages and licensed for home/self
therapy) and 1000 units for pdC1-INHCi (pdC1-INHCi is
approved in Europe for ages of 12 years and older by the
EMA; not approved for acute treatment of HAE attacks in
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USA). PdC1-INHCi is approved by the FDA and EMA for
prophylaxis for adolescents and adults and is licensed for
home/self-therapy. In Brazil, pdC1-INHBe is approved for
home/self-therapy and for pediatric and adult use (95, 99, 103–
107).
Ecallantide—Ecallantide is licensed by the FDA for the acute
treatment of HAE attacks in patients with C1-INH-HAE at the
age of 12 years and older (ecallantide is not licensed in Europe).
It is administered subcutaneously as a 30 mg dose (97). Hyper-
sensitivity, including anaphylaxis, is a known risk of ecallantide
treatment and occurs in 3% of treatments; no deaths are
reported (108). Because of the anaphylaxis risk, this drug
should be administered only by a healthcare professional who
has medical knowledge in the management of anaphylaxis.
Recombinant human C1-INH—rhC1-INH is licensed by the
FDA and EMA for the acute treatment of C1-INH-HAE for
the patients aged 13 and older (96, 109). An open-label treat-
ment study with rhC1-INH in a pediatric population (2–
13 years) is ongoing. The dose is 50 units per kg and is given
by intravenous injection.
Icatibant—Icatibant is licensed for acute treatment (including
home/self-treatment) of C1-INH-HAE for ages 18 years or
older by the FDA, EMA, ANVISA (Brazil) and other Latin
American countries (Table 2) (91, 92). Icatibant is not
licensed for pediatric use, but a clinical trial in pediatric
patients is ongoing.
Plasma—If licensed on-demand acute treatment medication
is not available or not accessible, 10 ml/kg of plasma may be
used on-demand—solvent detergent plasma is preferred over
fresh frozen plasma for safety reduction of risk of transfusion
transmitted diseases (level III evidence).
Therapeutic options and the license status are summarized
in Table 2.
Home-based treatment
Home therapy for hemophilia has been in use for more than
40 years (85, 110). Home-based acute treatment and prophy-
laxis of C1-INH-HAE has been recommended for all ages in
many consensus documents (22, 84, 85, 111, 112).
Formal approval of various agents for home therapy varies
by jurisdiction. Ecallantide, SDP, and FFP are not recom-
mended for self-therapy because of a small risk of anaphy-
laxis; however, in-home therapy by a nurse trained in the
treatment of anaphylaxis is an option for ecallantide (22, 90,
111–113).
Investigators have examined barriers to self-therapy from
the perspective of the nurse (114) and physician (111, 112, 114)
and more recently from the patient perspective (114–116). All
three components of the healthcare system agree that self-
care/self-home treatment is preferred despite these barriers.
Patients who do not perform self-treatment tend to overes-
timate the difficulties of training and of becoming proficient
in self-treatment (116). In contrast, patients who already
perform self-treatment are more confident in their training
and their ability to apply both subcutaneous and intravenous
injections (116). Although many physicians consider multiple
training appointments necessary (112), the majority of
patients performing self-treatment reported that it took them
only one or two sessions to feel competent enough for self-
administration.
Confidence is a large factor in patient’s adherence to treat-
ment and feeling of independence. One of the many benefits
of self-treatment therapy is greater freedom to live a normal
life at home, at school or work, or while traveling, leading to
improved overall QoL (116–119).
Comprehensive care centers and follow-up
We recommend following up the patient and family unit at
least once per year in an HAE comprehensive care center by
a consultant pediatrician C1-INH-HAE specialist with access
to endocrinology and psychology consultation if needed. For
patients on LTP who require closer monitoring, we suggest a
monitoring schedule of every three to six months. As with
other chronic illnesses, close attention should be paid to
growth and development (34). At these visits, the patient
diary, outpatient records, discharge summaries, and possible
treatment-emergent adverse events should be reviewed to
assess the disease severity and treatment tolerability and to
develop or adjust the treatment and prophylaxis strategies.
Patients on AA should see an endocrinologist at each visit.
Recommendations for adverse event screening while on LTP
with AA or TA are similar for pediatric patients as for adults
described in recent consensus documents. Between visits,
comprehensive care clinic support should be made available
via telephone or e-mail. The exchange of information should
be maintained with the family practitioner and/or pediatri-
cian (21, 22). The analysis of HRQoL outcomes at follow-up
visits may help in evaluating therapeutic effectiveness; but it
has to be kept in mind that QoL questionnaires currently
available for use in C1-INH-HAE have been validated only
in patients over 17 years of age (120). An adaptation of
HAE-QoL to pediatrics is planned.
International variation in availability of healthcare options
and levels of healthcare services
The knowledge about C1-INH-HAE diagnosis and therapy,
especially in pediatric patients, is still limited, particularly in
developing countries. A recent survey about C1-INH-HAE in
Latin America and the unavailability of data and medica-
tions in Latin America as in most African and Asian coun-
tries certainly influence the choice of therapy in these
countries (11). AAs have been used in pediatrics in many
developing countries because of the cost and lack of alterna-
tive medications although they are not recommended in the
guidelines nor before Tanner Stage V development. In light
of this, QoL, morbidity, and the possibility of mortality need
to be carefully balanced against the adverse effects of AAs
when making the decision to prescribe androgens to pediatric
patients (11, 121). Due to the rareness of the disease,
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Table 2 Therapeutic options—license status
Drug Registration
Indication
Age/Groups
†Acute treatment
Prophylaxis
Home
therapySTP LTP Children‡ Adolescence§
pdC1-INH (Berinert) Europe U U — U U U i.v.
USA U — — U U U
Latin America (Brazil,
Argentina, Mexico,
Colombia, Chile,
Puerto Rico)
U U — U U U i.v.
Australia U — — U — U i.v.
Canada U — — — — U i.v.
Israel U U — U U U i.v.
Japan U U — U — U i.v.
South Korea U U — U U U i.v.
pdC1-INH (Cinryze) Europe U U U U Trial ongoing U i.v.
USA — U U U Trial ongoing U
Latin America — — — — — — i.v.
Australia — U U U — — i.v.
Canada — U U U — — i.v.
Israel U U U U — — i.v.
rhC1-INH (Ruconest) Europe U — — — Trial ongoing U i.v.
USA U — — — Trial ongoing U
Latin America — — — — — —
Icatibant (Firazyr) Europe U — — U Trial ongoing Trial ongoing s.c.
USA U — — U Trial ongoing Trial ongoing
Latin America (Brazil,
Argentina, Mexico,
Colombia)
U — — U — — s.c.
Australia U — — U Trial ongoing Trial ongoing s.c.
Canada U — — U — — s.c.
Israel U — — U Trial ongoing Trial ongoing s.c.
Kuwait U — — U — — s.c.
South Africa U — — U — — s.c.
Attenuated androgens¶ Europe — U U — — U Oral
USA — — U — — —
Latin America (Brazil,
Argentina,
Mexico, Colombia)
— — U U — — Oral
Australia — — U — — — Oral
Tranexamic acid
(Cyklokapron;
Transamin;
Hemoblock)
Europe — — U — U U Oral
USA — — U — U U Oral
Canada — — U — U U Oral
Australia — — U — U U Oral
Latin America (Brazil,
Argentina, Mexico,
Colombia)
U — — U — — Oral
Ecallantide (Kalbitor) Europe — — — — — — s.c.
USA U — — — — U
Latin America — — — — — —
†i.v., intravenous; s.c., subcutaneous.
‡Children aged 0 to ≤12 years.
§Adolescents aged 12 to ≤18 years.
¶Attenuated androgens not licensed in Germany, Austria, and Switzerland.
pdC1-INH, human plasma-derived C1-INH; rhC1-INH, recombinant human C1-INH.
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emergency departments (EDs) are often unaware of the pro-
tocols for treating C1-INH-HAE attacks, particularly in
pediatrics. Establishing an effective approach to pediatric C1-
INH-HAE has been a challenge.
A recent publication reported that the average age at the
diagnosis of 25 pediatric patients evaluated in the USA was
7.2 years for patients mostly with a known positive family
history (5). In Brazil, the mean age at the diagnosis was
8.3  5.1 years with 94% of 50 patients (<18 years old)
being symptomatic (ASG, personal communication presented
in the 7th Budapest Workshop) (12).
Even though the patients had a known family history of
C1-INH-HAE and testing for C1-INH-HAE is generally rec-
ommended at an age of 1 year in this setting, a diagnosis in
these patients was only established after several years (5).
Unnecessary procedures are frequently reported in pediatric
patients with C1-INH-HAE (122). Zilberberg et al. (118)
evaluated emergency department (ED) visits of C1-INH-
HAE patients in the United States in 2006 and 2007. During
these two years, half of the 221 pediatric patients (<18 years
old) had to be hospitalized due to a C1-INH-HAE attack.
Because no drugs for attacks had been approved by the
FDA at that time, and only FFP was available for attacks,
this study could reflect the situation of patients with estab-
lished C1-INH-HAE diagnosis in countries where attack
therapy is not available as in most of Latin American, Asian,
or African countries. In addition, we should consider the
high cost of being treated in the ED in comparison with self-
treatment at home (106).
Estimation of the economic burden associated with C1-
INH-HAE is difficult and must reflect the costs for medical
interventions including hospital and outpatient care, prophy-
lactic and acute therapeutic medications, and also absen-
teeism of the parents and/or caregivers from work and
school absenteeism The true cost of the disease from medica-
tions alone in developed countries is frequently in many hun-
dred of thousands of US dollars per year. The cost of the
disease in developing countries without specific medications
for C1-INH-HAE is often excessive absenteeism, significant
morbidity, failure to maintain employment, and higher risk
of mortality (119, 123).
With the help of a parent or a guardian, pediatric patients
have successfully administered pdC1-INH concentrate, with
faster initiation of treatment, less time to symptom relief,
and fewer days of hospitalization and days lost from school.
In addition, even at a young age, pediatric patients can be
taught to safely administer intravenous and subcutaneous
therapy as is obvious from data from hemophilic patients
(90).
Conclusions
Phase III clinical trials are needed in the pediatric popula-
tions so that drug treatments for prophylaxis and acute ther-
apy are approved for all ages. New drug protocols should
include pediatric age patients for all rare diseases and use
these data to power and develop clinical trials specifically for
pediatrics. The future appears that medications will be deliv-
ered prophylactically by the subcutaneous and oral routes,
which will reduce the stress of frequent intravenous injec-
tions. Long-term follow-up programs are essential in pedi-
atric patients as these cohorts represent unique populations
at risk for adverse events given the growth phases and devel-
opmental changes in this population. International registries
for pediatric patients with C1-INH-HAE disease will facili-
tate safety and efficacy data and allow earlier detection of
long-term adverse event and benefits of specific interventions.
In summary, more therapeutic trials, data on dosing by
weight, databases, and data to support self-administration
programs are needed to further the science and clinical care
of the pediatric population with C1-INH-HAE.
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